These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 23536435)
1. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Broniscer A; Baker SD; Wetmore C; Pai Panandiker AS; Huang J; Davidoff AM; Onar-Thomas A; Panetta JC; Chin TK; Merchant TE; Baker JN; Kaste SC; Gajjar A; Stewart CF Clin Cancer Res; 2013 Jun; 19(11):3050-8. PubMed ID: 23536435 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. Broniscer A; Baker JN; Tagen M; Onar-Thomas A; Gilbertson RJ; Davidoff AM; Pai Panandiker AS; Leung W; Chin TK; Stewart CF; Kocak M; Rowland C; Merchant TE; Kaste SC; Gajjar A J Clin Oncol; 2010 Nov; 28(31):4762-8. PubMed ID: 20921456 [TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900 [TBL] [Abstract][Full Text] [Related]
4. Repurposing Vandetanib plus Everolimus for the Treatment of Carvalho DM; Richardson PJ; Olaciregui N; Stankunaite R; Lavarino C; Molinari V; Corley EA; Smith DP; Ruddle R; Donovan A; Pal A; Raynaud FI; Temelso S; Mackay A; Overington JP; Phelan A; Sheppard D; Mackinnon A; Zebian B; Al-Sarraj S; Merve A; Pryce J; Grill J; Hubank M; Cruz O; Morales La Madrid A; Mueller S; Carcaboso AM; Carceller F; Jones C Cancer Discov; 2022 Feb; 12(2):416-431. PubMed ID: 34551970 [TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors. Kaste SC; Kaufman RA; Gajjar A; Broniscer A Pediatr Blood Cancer; 2013 Sep; 60(9):1552-6. PubMed ID: 23526749 [TBL] [Abstract][Full Text] [Related]
6. Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy. Patay Z; Merchant TE; Nguyen R; Pierson CR; Onar-Thomas A; Broniscer A Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1295-1305. PubMed ID: 29165288 [TBL] [Abstract][Full Text] [Related]
7. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652 [TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. Gibson EG; Campagne O; Selvo NS; Gajjar A; Stewart CF Cancer Chemother Pharmacol; 2021 Dec; 88(6):1009-1020. PubMed ID: 34586478 [TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Haas-Kogan DA; Banerjee A; Kocak M; Prados MD; Geyer JR; Fouladi M; McKnight T; Poussaint TY; Broniscer A; Blaney SM; Boyett JM; Kun LE Neuro Oncol; 2008 Jun; 10(3):341-7. PubMed ID: 18417739 [TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822 [TBL] [Abstract][Full Text] [Related]
13. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Secord AA; Teoh DK; Barry WT; Yu M; Broadwater G; Havrilesky LJ; Lee PS; Berchuck A; Lancaster J; Wenham RM Clin Cancer Res; 2012 Oct; 18(19):5489-98. PubMed ID: 22837181 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Pollack IF; Jakacki RI; Blaney SM; Hancock ML; Kieran MW; Phillips P; Kun LE; Friedman H; Packer R; Banerjee A; Geyer JR; Goldman S; Poussaint TY; Krasin MJ; Wang Y; Hayes M; Murgo A; Weiner S; Boyett JM Neuro Oncol; 2007 Apr; 9(2):145-60. PubMed ID: 17293590 [TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. Haura EB; Tanvetyanon T; Chiappori A; Williams C; Simon G; Antonia S; Gray J; Litschauer S; Tetteh L; Neuger A; Song L; Rawal B; Schell MJ; Bepler G J Clin Oncol; 2010 Mar; 28(8):1387-94. PubMed ID: 20142592 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385 [TBL] [Abstract][Full Text] [Related]
17. A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. Hipp SJ; Goldman S; Kaushal A; Krauze A; Citrin D; Glod J; Walker K; Shih JH; Sethumadhavan H; O'Neill K; Garvin JH; Glade-Bender J; Karajannis MA; Atlas MP; Odabas A; Rodgers LT; Peer CJ; Savage J; Camphausen KA; Packer RJ; Figg WD; Warren KE J Neurooncol; 2020 Sep; 149(3):437-445. PubMed ID: 33040274 [TBL] [Abstract][Full Text] [Related]
18. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature. Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549 [TBL] [Abstract][Full Text] [Related]
20. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Burzynski SR; Janicki TJ; Burzynski GS; Marszalek A Childs Nerv Syst; 2014 Dec; 30(12):2051-61. PubMed ID: 24718705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]